Daxor Corporation Total Liabilities
Daxor Corporation total liabilities. Based on the latest financial reports, Daxor Corporation (DXR) has total liabilities worth $272.43K USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Daxor Corporation asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Daxor Corporation (1985–2024)
Total liabilities of Daxor Corporation from 1985 to 2024. This chart illustrates how Daxor Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore DXR strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Daxor Corporation Competitors by Total Liabilities
The table below lists competitors of Daxor Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
eMedia Holdings Limited
JSE:EMN
|
South Africa | ZAC1.80 Billion |
|
Shuang-Bang Industrial
TWO:6506
|
Taiwan | NT$1.23 Billion |
|
Bonus Biogroup
TA:BONS
|
Israel | ILA21.11 Million |
|
Sangsangin Ian No.1 Special Purpose Acquisition Co. Ltd
KQ:307870
|
Korea | ₩29.02 Billion |
|
Krungdhep Sophon Public Company Limited
BK:KWC
|
Thailand | ฿129.92 Million |
|
Logan Ridge Finance Corp
NASDAQ:LRFC
|
USA | $101.89 Million |
|
Yatra Online Inc
NASDAQ:YTRA
|
USA | $5.56 Billion |
Liability Composition Analysis (1985–2024)
This chart breaks down Daxor Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Daxor Corporation.
Liquidity & Leverage Metrics
Daxor Corporation Total Liabilities Ratios Explained
Daxor Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | N/A | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daxor Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daxor Corporation (1985–2024)
The table below shows the annual total liabilities of Daxor Corporation from 1985 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $840.30K | -2.15% |
| 2023-12-31 | $858.76K | -33.51% |
| 2022-12-31 | $1.29 Million | -66.27% |
| 2021-12-31 | $3.83 Million | +336.26% |
| 2020-12-31 | $877.69K | -38.85% |
| 2019-12-31 | $1.44 Million | -68.55% |
| 2018-12-31 | $4.56 Million | -17.81% |
| 2017-12-31 | $5.55 Million | +5.18% |
| 2016-12-31 | $5.28 Million | -18.34% |
| 2015-12-31 | $6.47 Million | -69.88% |
| 2014-12-31 | $21.47 Million | +2.10% |
| 2013-12-31 | $21.02 Million | -0.91% |
| 2012-12-31 | $21.22 Million | -57.15% |
| 2011-12-31 | $49.51 Million | +12.01% |
| 2010-12-31 | $44.20 Million | +60.37% |
| 2009-12-31 | $27.56 Million | -17.39% |
| 2008-12-31 | $33.36 Million | -29.97% |
| 2007-12-31 | $47.64 Million | +46.47% |
| 2006-12-31 | $32.53 Million | +56.23% |
| 2005-12-31 | $20.82 Million | +29.74% |
| 2004-12-31 | $16.05 Million | +35.05% |
| 2003-12-31 | $11.88 Million | +48.05% |
| 2002-12-31 | $8.03 Million | -2.25% |
| 2001-12-31 | $8.21 Million | -24.69% |
| 2000-12-31 | $10.90 Million | +66.04% |
| 1999-12-31 | $6.57 Million | -25.38% |
| 1998-12-31 | $8.80 Million | +4.76% |
| 1997-12-31 | $8.40 Million | +52.73% |
| 1996-12-31 | $5.50 Million | -1.79% |
| 1995-12-31 | $5.60 Million | +43.59% |
| 1994-12-31 | $3.90 Million | -17.02% |
| 1993-12-31 | $4.70 Million | -54.37% |
| 1992-12-31 | $10.30 Million | +1.98% |
| 1991-12-31 | $10.10 Million | -9.01% |
| 1990-12-31 | $11.10 Million | +42.31% |
| 1989-12-31 | $7.80 Million | -30.97% |
| 1988-12-31 | $11.30 Million | +44.87% |
| 1987-12-31 | $7.80 Million | +11.43% |
| 1986-12-31 | $7.00 Million | +52.17% |
| 1985-12-31 | $4.60 Million | -- |
About Daxor Corporation
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corpo… Read more